Wire flash
FinanceAurobindo arm CuraTeQ Biologics' facility secures nod from Brazil's health regulator
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Aurobindo Pharma's subsidiary CuraTeQ Biologics has received approval from Brazil's health regulator Anvisa for its biosimilars manufacturing facility in Hyderabad, India. The facility underwent a Good Manufacturing Practice (GMP) inspection by Anvisa from May 11-15, 2026, covering four biosimilar products, mammalian and microbial drug substance manufacturing, prefillable syringe and vial filling, packaging, labeling, and QC testing. The approval enables CuraTeQ to enter the broader Latin American market. The facility is already certified by the European Medicines Agency (EMA) and the World Health Organization (WHO), underscoring its global compliance standards.
Source report
The facility underwent a good manufacturing practice (GMP) inspection by Anvisa from May 11–15, 2026
Published: July 21, 2026 06:53 pm IST | Location: HYDERABAD
By: The Hindu Bureau
Aurobindo Pharma subsidiary CuraTeQ Biologics’ biosimilars manufacturing facility in Hyderabad has received approval from Brazilian health regulator Anvisa, enabling the company to access the broader Latin American market.
The facility underwent a good manufacturing practice (GMP) inspection by Anvisa from May 11–15, 2026. The approval was granted following the successful completion of the inspection for biological active pharmaceutical ingredient (API) and sterile products, Aurobindo Pharma said in a filing on Tuesday.
The scope of the GMP inspection covered four biosimilar products and assessed:
- The mammalian and microbial drug substance manufacturing facility
- Prefillable syringe and vial filling facility
- Packaging and labelling facility
- QC testing and release laboratories
Aurobindo stated that CuraTeQ’s drug substance and drug product GMP facility is European Medicines Agency (EMA) and WHO certified. The Anvisa approval reaffirms the company’s commitment to global regulatory compliance and quality standards.
Source
The Hindu: Latest News today from India and the World, Breaking news, Top Headlines and Trending News Videos.Regional
Part of this Story
Aurobindo arm CuraTeQ Biologics’ facility secures nod from Brazil’s health regulator